Table 1. Patients’ characteristics.

Patient	Pre-op staging (TNM)	Pathological staging (TNM)	Pathological staging group (AJCC)	Histology	Time to CNS metastasis (days)	Size mm
1	T3 N0 M0	pT2b Nx Mx R0	IIB	Squamous cell	1032	30 mm
2	T4N0M0	pT4 pN0 Mx R0	IIIA	Adenocarcinoma	696	27 mm
3	T1bN0M0	pT1b pN0 MX R0	IA	Adenocarcinoma	420	35 mm
4	T2bN2M0	pT2b pN0 Mx R0	IIIA	Basaloid	374	20 mm
5	T2aN2M0	pT3 pN0 Mx R0	IIB	Squamous cell	241	32 mm
6	T1bN0M0	pT1a Nx Mx R0	IA	Adenocarcinoma	694	45 mm
7	Not available	pT3 pN1 MX R0	IIIA	Adenocarcinoma	14	18 mm
8	T2bN0M0	pT2b pN1 MX R0	IIB	Adenocarcinoma	68	16 mm
9	T3N1M0	pT3 pN1 MX R0	IIIA	Adenocarcinoma	295	38 mm
10	T3N2M0	pT3 pN1 MX R0	IIIA	Adenocarcinoma	245	37 mm
11	Not available	pT3 pN1 MX R0	IIIA	Squamous cell	Not available	28 mm
12	T2aN0M0	pT2a, pN0 Mx R0	IB	Adenocarcinoma	103	28 mm
13	T1aN0M0	pT1a pN0 MX R0	IA	Large cell neuroendocrine	281	44 mm
14	T2bN0M0	pT3 pN1 Mx R0	IIIA	Adenocarcinoma	788	32 mm
15	T3N0M0	pT3 pN0 Mx R1	IIB	Squamous cell	145	22 mm
16	T1bN0M0	pT3 pN0 MX R0	IIB	Adenocarcinoma	386	28 mm
17	T2aN1M0	pT1b pN0 pMX R0	IA	Adenocarcinoma	161	18 mm
18	T1bN0M0	pT2a pN1 pMX R0	IIA	Adenocarcinoma	368	16 mm